SCHEDULE: Armistice Capital Boosts Kura Oncology Stake to 7.14%

Armistice Capital, LLC and Steven Boyd have disclosed a beneficial ownership of 7.14% in Kura Oncology, Inc., holding 6.2 million shares.

Summary

• Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 6,200,000 shares of Kura Oncology, Inc. Common Stock.
• This ownership represents 7.14% of the company's outstanding shares.
• The percentage is based on 86,797,185 shares outstanding as of August 1, 2025, as reported in Kura Oncology's Form 10-Q filed on August 7, 2025.
• Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC and is deemed to beneficially own the shares held by the Master Fund.
• Both reporting persons hold shared voting and shared dispositive power over all 6,200,000 shares.

Sentiment

Score: 7

Explanation: The filing indicates a significant new or increased stake by a reputable investment firm, which is generally viewed as a positive signal of confidence in the company's prospects.

Positives

• A significant stake of 7.14% acquired by Armistice Capital, LLC and Steven Boyd indicates a strong vote of confidence from a sophisticated institutional investor in Kura Oncology, Inc.

Risks

• The filing itself, being a Schedule 13G, does not detail specific operational or financial risks of Kura Oncology, Inc., but rather discloses an ownership stake.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Kura Oncology, Inc.'s future performance or outlook.

Industry Context

This filing indicates increased institutional interest in Kura Oncology, a biotechnology company focused on oncology. Such investments can signal perceived value or strategic positioning within the competitive biotech landscape, particularly for companies developing novel cancer therapies.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may positively influence market perception and potentially the share price, signaling confidence from a major investor.
• Management: Increased institutional ownership may lead to greater scrutiny or engagement from the new significant shareholder regarding corporate strategy and performance.

Key Dates

Recommendation

The acquisition of a 7.14% stake by Armistice Capital, a sophisticated investment firm, suggests a strong belief in Kura Oncology's value proposition. This institutional vote of confidence could be a positive indicator for other investors, warranting a 'buy' recommendation based on the signal of smart money entering the stock.

Keywords

Kura Oncology, Armistice Capital, Steven Boyd, Biotechnology, Oncology, Institutional Investment, Shareholder, SEC Filing, Common Stock